Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Description

To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).

Conditions

Non-Traumatic Subarachnoid Hemorrhage

Talk to us

Study Overview

On this page

Study Details

Study overview

To determine the effect of early metoprolol administration after non-traumatic subarachnoid hemorrhage (SAH).

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Beta-1 Adrenergic Inhibition to Reduce Cardiac Injury and Inflammation After Subarachnoid Hemorrhage (BADCATS)

Condition
Non-Traumatic Subarachnoid Hemorrhage
Intervention / Treatment

-

Contacts and Locations

Portland

MaineHealth, Portland, Maine, United States, 04012

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * \>18 years of age
  • * Neuro-imaging confirmed non-traumatic subarachnoid hemorrhage
  • * Traumatic cause of subarachnoid hemorrhage (e.g. fall, motor vehicle accident, other blunt trauma) as this is a different mechanism of hemorrhage.
  • * Other forms of traumatic or non-traumatic intracranial bleed including intracerebral hemorrhage (ICH), subdural hemorrhage, epidural hemorrhage
  • * Pregnancy (as the study medication, metoprolol, has FDA Pregnancy Category C rating)
  • * Unstable vital signs not amenable to beta-1 adrenergic receptor inhibitor (B1ARi) administration including:
  • * Systolic blood pressure \< 80 mmHg not stabilized on vasopressor medications
  • * Heart rate \< 50 bpm associated with hypotension
  • * Patients requiring vasopressor agents due to hypotension (SBP \<80 mmHg)
  • * Other vital sign exclusion at the discretion of the treatment team
  • * Previous history of severe heart failure (Stage C or D Heart Failure and/or NYHA Class III or IV)
  • * Patient or legally authorized representative unwilling to provide informed consent

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Madeleine Puissant,

Madeleine Puissant, MD, PhD, PRINCIPAL_INVESTIGATOR, MaineHealth

Study Record Dates

2029-09